BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zopf S, Kremer AE, Neurath MF, Siebler J. Advances in hepatitis C therapy: What is the current state - what come’s next? World J Hepatol 2016; 8(3): 139-147 [PMID: 26839638 DOI: 10.4254/wjh.v8.i3.139] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Sebastiani G, Wilkinson N, Pantopoulos K. Pharmacological Targeting of the Hepcidin/Ferroportin Axis. Front Pharmacol 2016;7:160. [PMID: 27445804 DOI: 10.3389/fphar.2016.00160] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
2 Selvapatt N, Brown A. A real-world intention-to-treat analysis of a decade's experience of treatment of hepatitis C with interferon-based therapies. F1000Res 2016;5:2061. [PMID: 27746906 DOI: 10.12688/f1000research.9114.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Trucchi C, Orsi A, Alicino C, Sticchi L, Icardi G, Ansaldi F. State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. J Immunol Res 2016;2016:1412840. [PMID: 27843956 DOI: 10.1155/2016/1412840] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 El Raziky M, Hamdy S, Hamada Y, Abdelaziz NM, Hassany M, Doss W, Zakaria Z. Efficacy and safety of sofosbuvir and daclatasvir in patients with chronic hepatitis C virus induced cirrhosis with Child-Pugh class B. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00174-3] [Reference Citation Analysis]
5 Sanna A, Le Strat Y, Roudot-Thoraval F, Deuffic Burban S, Carrieri P, Delarocque-Astagneau E, Larsen C. Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014. Euro Surveill 2017;22:30582. [PMID: 28797326 DOI: 10.2807/1560-7917.ES.2017.22.30.30582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Figueiredo AS, Lampe E, de Albuquerque PPLF, Chalhoub FLL, de Filippis AMB, Villar LM, Cruz OG, Pinto MA, de Oliveira JM. Epidemiological investigation and analysis of the NS5B gene and protein variability of non-primate hepacivirus in several horse cohorts in Rio de Janeiro state, Brazil. Infect Genet Evol 2018;59:38-47. [PMID: 29413884 DOI: 10.1016/j.meegid.2018.01.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Lagaye S, Brun S, Gaston J, Shen H, Stranska R, Camus C, Dubray C, Rousseau G, Massault PP, Courcambeck J, Bassisi F, Halfon P, Pol S. Anti-hepatitis C virus potency of a new autophagy inhibitor using human liver slices model. World J Hepatol 2016; 8(21): 902-914 [PMID: 27478540 DOI: 10.4254/wjh.v8.i21.902] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Jessop AB, Bass SB, Brajuha J, Alhajji M, Burke M, Gashat MT, Wellington C, Ventriglia N, Coleman J, D'Avanzo P. "Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy. J Subst Abuse Treat 2020;109:23-33. [PMID: 31856947 DOI: 10.1016/j.jsat.2019.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Castelli M, Clementi N, Pfaff J, Sautto GA, Diotti RA, Burioni R, Doranz BJ, Dal Peraro M, Clementi M, Mancini N. A Biologically-validated HCV E1E2 Heterodimer Structural Model. Sci Rep 2017;7:214. [PMID: 28303031 DOI: 10.1038/s41598-017-00320-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
10 Hayes CN, Chayama K. Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses: ISGs in HCV and HBV Infection. J Med Virol 2017;89:388-96. [DOI: 10.1002/jmv.24659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
11 Mani N, Cole AG, Phelps JR, Ardzinski A, Cobarrubias KD, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Guo H, Guo JT, Harasym TO, Kadhim S, Kultgen SG, Lee ACH, Li AHL, Long Q, Majeski SA, Mao R, McClintock KD, Reid SP, Rijnbrand R, Snead NM, Micolochick Steuer HM, Stever K, Tang S, Wang X, Zhao Q, Sofia MJ. Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation. Antimicrob Agents Chemother. 2018;62:e00082-18. [PMID: 29555628 DOI: 10.1128/aac.00082-18] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
12 Grottenthaler JM, Werner CR, Steurer M, Spengler U, Berg T, Engelmann C, Wedemeyer H, von Hahn T, Stremmel W, Pathil A, Seybold U, Schott E, Blessin U, Sarrazin C, Welker MW, Harrer E, Scholten S, Hinterleitner C, Lauer UM, Malek NP, Berg CP. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation. PLoS One 2018;13:e0197544. [PMID: 29874250 DOI: 10.1371/journal.pone.0197544] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bass SB, Jessop A, Maurer L, Gashat M, Al Hajji M, Gutierrez M. Mapping the Barriers and Facilitators of HCV Treatment Initiation in Methadone Maintenance Therapy Patients: Implications for Intervention Development. J Health Commun 2018;23:117-27. [PMID: 29252118 DOI: 10.1080/10810730.2017.1414902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
14 Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opin Investig Drugs 2018;27:243-50. [PMID: 29271672 DOI: 10.1080/13543784.2018.1420780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Esforzado N, Morales JM. Hepatitis C and kidney transplant: The eradication time of the virus has arrived. Nefrologia (Engl Ed) 2019;39:458-72. [PMID: 30905391 DOI: 10.1016/j.nefro.2019.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Phillips M, Abboud J, Abodunde B, Paul DP 3rd, Coustasse A. The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia. Health Care Manag (Frederick) 2020;39:2-11. [PMID: 31876587 DOI: 10.1097/HCM.0000000000000278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Minosse C, Giombini E, Bartolini B, Capobianchi MR, Garbuglia AR. Ultra-Deep Sequencing Characterization of HCV Samples with Equivocal Typing Results Determined with a Commercial Assay. Int J Mol Sci 2016;17:E1679. [PMID: 27739414 DOI: 10.3390/ijms17101679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
18 Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, Möller H, Moucheraud C, Pécoul B, Rägo L, Rashidian A, Ross-Degnan D, Stephens PN, Teerawattananon Y, 't Hoen EF, Wagner AK, Yadav P, Reich MR. Essential medicines for universal health coverage. Lancet 2017;389:403-76. [PMID: 27832874 DOI: 10.1016/S0140-6736(16)31599-9] [Cited by in Crossref: 208] [Cited by in F6Publishing: 106] [Article Influence: 34.7] [Reference Citation Analysis]
19 Taherkhani R, Farshadpour F. Lurking epidemic of hepatitis C virus infection in Iran: A call to action. World J Hepatol 2017; 9(24): 1040-1042 [PMID: 28932350 DOI: 10.4254/wjh.v9.i24.1040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
20 Yang Y, Dang SS. Safety of direct antiviral agents for treatment of hepatitis C virus infection. Shijie Huaren Xiaohua Zazhi 2017; 25(8): 659-669 [DOI: 10.11569/wcjd.v25.i8.659] [Reference Citation Analysis]
21 Sotiropoulos GC, Machairas N, Stamopoulos P, Kostakis ID, Dimitroulis D, Mantas D, Kouraklis G. Laparoscopic versus open liver resection for hepatocellular carcinoma: initial experience in Greece. Ann Gastroenterol 2016;29:521-9. [PMID: 27708521 DOI: 10.20524/aog.2016.0067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
22 Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res 2018;147:445-55. [PMID: 30082568 DOI: 10.4103/ijmr.IJMR_1850_16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Bell AM, Wagner JL, Barber KE, Stover KR. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. Int J Hepatol. 2016;2016:3852126. [PMID: 27403342 DOI: 10.1155/2016/3852126] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
24 Bonaventura A, Montecucco F. Sofosbuvir/velpatasvir: A promising combination. World J Hepatol 2016; 8(19): 785-789 [PMID: 27429714 DOI: 10.4254/wjh.v8.i19.785] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
25 Chasser Y, Kim AY, Freudenreich O. Hepatitis C Treatment: Clinical Issues for Psychiatrists in the Post-Interferon Era. Psychosomatics 2017;58:1-10. [PMID: 27871760 DOI: 10.1016/j.psym.2016.09.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
26 Agrawal B, Kumar R. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses. World J Gastroenterol 2016; 22(25): 5623-5626 [PMID: 27433078 DOI: 10.3748/wjg.v22.i25.5623] [Reference Citation Analysis]
27 Nguyen CB, Houchen CW, Ali N. APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. Exp Biol Med (Maywood) 2017;242:242-9. [PMID: 27694285 DOI: 10.1177/1535370216672746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
28 Marciano S, Haddad L, Plazzotta F, Mauro E, Terraza S, Arora S, Thornton K, Ríos B, García Dans C, Ratusnu N, Calanni L, Allevato J, Sirotinsky ME, Pedrosa M, Gadano A. Implementation of the ECHO® telementoring model for the treatment of patients with hepatitis C. J Med Virol 2017;89:660-4. [PMID: 27551942 DOI: 10.1002/jmv.24668] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
29 Twagirumugabe T, Swaibu G, Bergström T, Walker TD, Gahutu JB, Norder H. Low prevalence of hepatitis C virus RNA in blood donors with anti-hepatitis C virus reactivity in Rwanda. Transfusion 2017;57:2420-32. [PMID: 28671283 DOI: 10.1111/trf.14204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Bauerle Bass S, Jessop A, Gashat M, Maurer L, Alhajji M, Forry J. Take Charge, Get Cured: The development and user testing of a culturally targeted mHealth decision tool on HCV treatment initiation for methadone patients. Patient Educ Couns 2018;101:1995-2004. [PMID: 30055893 DOI: 10.1016/j.pec.2018.07.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
31 Izzo I, Zanotti P, Chirico C, Casari S, Villanacci V, Salemme M, Biasi L, Festa E, Castelli F. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C. Infection 2016;44:811-2. [PMID: 27311809 DOI: 10.1007/s15010-016-0915-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
32 Chown H. A comparison of machine learning algorithms for the prediction of Hepatitis C NS3 protease cleavage sites. The EuroBiotech Journal 2019;3:167-74. [DOI: 10.2478/ebtj-2019-0020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
33 Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 2016;15:1145-1160. [PMID: 27640316 DOI: 10.1016/j.autrev.2016.09.006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 10.5] [Reference Citation Analysis]
34 Zopf S, Rösch L, Konturek PC, Goertz RS, Neurath MF, Strobel D. Low Pretreatment Acoustic Radiation Force Impulse Imaging (ARFI) Values Predict Sustained Virological Response in Antiviral Hepatitis C Virus (HCV) Therapy. Med Sci Monit 2016;22:3500-5. [PMID: 27690214 DOI: 10.12659/msm.896344] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
35 Tadokoro T, Morishita A, Oura K, Fujita K, Mimura S, Sakamoto T, Nomura T, Tani J, Yoneyama H, Masaki T. Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report. Exp Ther Med 2018;16:1026-8. [PMID: 30116355 DOI: 10.3892/etm.2018.6207] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, Frikeche J, Lott T, Felder R, Scotland SJ, Eisinger-mathason TSK, Brem H, Tyler B, Skuli N. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. Oncogene 2017;36:3037-47. [DOI: 10.1038/onc.2016.457] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
37 Ito W, Toyama M, Okamoto M, Ikeda M, Watashi K, Wakita T, Hashimoto Y, Baba M. Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative. Antivir Chem Chemother 2015;24:148-54. [PMID: 27503576 DOI: 10.1177/2040206616663956] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018;38:443-450. [PMID: 28756625 DOI: 10.1111/liv.13534] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
39 Kaptein SJ, Neyts J. Towards antiviral therapies for treating dengue virus infections. Current Opinion in Pharmacology 2016;30:1-7. [DOI: 10.1016/j.coph.2016.06.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 6.5] [Reference Citation Analysis]
40 Xu HT, Hassounah SA, Colby-Germinario SP, Oliveira M, Fogarty C, Quan Y, Han Y, Golubkov O, Ibanescu I, Brenner B, Stranix BR, Wainberg MA. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. J Antimicrob Chemother 2017;72:727-34. [PMID: 28069884 DOI: 10.1093/jac/dkw514] [Cited by in Crossref: 24] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
41 Couronné L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, Canioni D, Michot JM, Visco C, Arcaini L, Besson C, Hermine O. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol 2018;29:92-100. [PMID: 29045541 DOI: 10.1093/annonc/mdx635] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
42 Yap JE, Jaiswal P, Ton L, Szynkarek R, Attar BM, Gandhi S. Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube. J Clin Pharm Ther 2018;43:730-2. [DOI: 10.1111/jcpt.12713] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]